Borate Incorporation in Bioactive Glass: Dissolution Rate

Overview of Technical Issues:

The borate-modified glass network exhibits insufficient control over dissolution rate because borate incorporation disrupts silicate network connectivity through weaker B-O bonds and increased non-bridging oxygens, resulting in accelerated and potentially uncontrolled ion release that may exceed the optimal therapeutic window or cause premature structural degradation; the goal is to optimize borate content to balance enhanced bioactive ion delivery with maintained structural integrity throughout the tissue regeneration period.

Solution directions generated for this problem

Problem Direction 1 :

ImproveNetwork bond strength
VS
ConstraintBioactive ion release rate

Inspiration 1 : Cross-domain reference

Application Principle: #35 Parameter changes
Cross-domain applicability Assess applicability
Pharmaceutical composition and administrations thereof
Innovative Solution Refine solution

Dual-phase glass with crystalline borate inclusions for decoupled network strength and ion release

Decouple structure from release via phase separation
How to solve :
  • Synthesize base glass with 3-5 wt% boron in silicate network (Si-O bonds ~799 kJ/mol) for 8-12 week structural integrity, then incorporate 15-20 vol% crystalline calcium borate (Ca₃B₂O₆) particles (50-150 μm) that dissolve independently at 15-20 ppm/day without weakening matrix
  • Melt base glass at 1400°C for 2h, cool to 900°C, add pre-synthesized calcium borate powder, stir 30 min, cast and anneal at 550°C for 4h to achieve uniform particle dispersion and stress relief
  • Control particle size distribution (D50=100±20 μm) via sieving, verify dispersion homogeneity by SEM (≥90% particles within 80-120 μm spacing), measure boron release kinetics in simulated body fluid maintaining 12-18 ppm over 12 weeks (acceptance: ±3 ppm variance)
Expected Effect : Matrix bond strength 750-780 kJ/mol, 8-12 week stability; ion release 15±3 ppm/day for 12 weeks; 40% stronger than homogeneous borate glass
Risk Control :
  • calcium borate particle agglomeration during mixing
  • thermal expansion mismatch causing microcracking
  • particle dissolution rate variability from size distribution

Problem Direction 2 :

ImproveNetwork bond strength
VS
ConstraintTherapeutic ion concentration

Inspiration 1 : Cross-domain reference

Application Principle: #3 Local quality
Cross-domain applicability Assess applicability
Compositional variations of tungsten tetraboride with transition metals and light elements
Innovative Solution Refine solution

Radial compositional gradient glass scaffold with zone-specific boron distribution

Design radial gradient scaffold with boron-rich outer zone for early ion delivery
How to solve :
  • Fabricate three-zone radial gradient structure: outer zone (0–200 μm depth) with 14–16 wt% boron dissolves in weeks 1–4 maintaining 15–25 ppm therapeutic window
  • middle transition zone (200–500 μm) with 7–9 wt% boron provides weeks 5–8 sustained release at 8–12 ppm
  • inner core (>500 μm) with 3–4 wt% boron and Si-O bond-dominated network (bond energy ~750 kJ/mol) maintains structural integrity through weeks 9–12
  • Achieve gradient via sequential dip-coating in borosilicate sols with decreasing B₂O₃ content (outer: 16 mol% B₂O₃, middle: 9 mol%, core: 3 mol%), sintering at 1100–1200°C under controlled atmosphere, cooling rate 2°C/min to minimize thermal stress and ensure gradient stability
  • Implement quality control via micro-XRF mapping (spatial resolution ≤50 μm) to verify boron concentration profile matches design (tolerance ±1.5 wt% per zone), measure zone-specific dissolution rates in simulated body fluid at 37°C (outer zone: 18±3 ppm/day weeks 1–4, core: <2 ppm/day weeks 9–12), and confirm compressive strength ≥80 MPa at week 8 via mechanical testing
Expected Effect : Therapeutic ion flux 15–25 ppm weeks 1–4, structural stability 8–12 weeks, compressive strength ≥80 MPa
Risk Control :
  • gradient interface delamination during sintering
  • boron volatilization causing composition deviation
  • dissolution rate variability between batches

Problem Direction 3 :

ImproveStructural stability duration
VS
ConstraintBioactive ion release rate

Inspiration 1 : Cross-domain reference

Application Principle: #19 Periodic action
Cross-domain applicability Assess applicability
A three-layer controlled-release tablet of acemetidine and its preparation method
Innovative Solution Refine solution

Pulsed-release boron scaffold with dissolvable gate bands

Timed boron pulses from bands
How to solve :
  • Build a low-borate silicate core with 3-5 wt% B2O3, 45-55 wt% SiO2, sinter at 680-720°C for 30-60 min to keep compressive strength 8-12 MPa for 8-12 weeks
  • Add circumferential boron-rich release bands of 10-12 wt% B2O3 separated by 50-80 μm phosphate-glass gate layers, tape-cast or dip-coat 3-4 cycles, each band 80-120 μm thick for staged exposure every 7-14 days
  • Control by micro-CT, ICP-OES, and mass-loss tests: layer thickness ±10 μm, porosity 60-75%, boron release 10-20 ppm/day in weeks 1-4 and 5-12 ppm/day after, acceptance if 8-week mass retention is 45-60%
Expected Effect : B release 10-20 ppm/day early, stability 8-12 weeks, release CV below 15%, strength retention above 50% at week 8
Risk Control :
  • gate layer cracking
  • band delamination
  • release pulse timing drift

Problem Direction 4 :

ImproveDissolution rate controllability
VS
ConstraintTherapeutic ion concentration

Inspiration 1 : Cross-domain reference

Application Principle: #35 Parameter changes
Cross-domain applicability Assess applicability
Process and intermediates for preparing prodrugs of pyridone amides useful as modulators of sodium channels
Innovative Solution Refine solution

Crystalline calcium borate reservoir glass for stable boron dosing

Separate boron into stable reservoirs
How to solve :
  • Build low-borate silicate matrix with 3-5 wt% network B2O3, melt 1450-1500°C, porosity 60-75%, compressive strength >8 MPa
  • Disperse crystalline CaB2O4 reservoirs at 8-12 vol%, particle size 5-20 μm, sinter 680-720°C so boron release comes from inclusions not backbone
  • Control by XRD ICP and micro-CT: CaB2O4 crystallinity >85%, particle CV <10%, B release 10-30 ppm/day for 28 d, mass loss 35-55% at 8 weeks, residual strength >50%, inspect each lot by ISO 10993 extract test
Expected Effect : B window 10-50 ppm, release CV <15%, support 8-12 weeks, early burst cut >40%
Risk Control :
  • reservoir agglomeration
  • excess crystal fraction embrittlement
  • batch release drift

Problem Direction 5 :

ImproveStructural stability duration
VS
ConstraintTherapeutic ion concentration

Inspiration 1 : Cross-domain reference

Application Principle: #1 Segmentation
Cross-domain applicability Assess applicability
Reference signal reception and CQI computation method and wireless communication apparatus
Innovative Solution Refine solution

Functionally-partitioned dual-zone borate glass scaffold with independent structural and therapeutic domains

Partition scaffold into independent zones
How to solve :
  • Fabricate scaffold with discrete structural domain (3-5 wt% boron, Si-O bond-dominant network, 799 kJ/mol) occupying 70-75 vol% for 8-12 week mechanical integrity, and therapeutic domain (15-18 wt% boron, rapid-dissolving calcium borate phase) occupying 25-30 vol% for ion delivery
  • Manufacture via co-sintering technique: press low-borate glass powder (particle size 20-45 μm) into scaffold framework at 650-700°C for 2 hours, then infiltrate pores with high-borate sol-gel precursor (B₂O₃:CaO:SiO₂ = 40:35:25 mol%) and cure at 500-550°C for 1 hour to form discrete therapeutic inclusions
  • Control therapeutic domain dissolution kinetics by adjusting calcium borate crystallinity (XRD peak intensity ratio I₂₉₀/I₃₁₅ = 1.2-1.8) via cooling rate (2-5°C/min) to achieve 15-22 ppm/day boron release during weeks 1-4, then taper to 3-6 ppm/day as structural domain remains intact through week 12
Expected Effect : Structural integrity maintained ≥8 weeks (compressive strength ≥25 MPa); therapeutic window 10-50 ppm sustained weeks 1-4; total boron inventory 8.5-10 wt% equivalent
Risk Control :
  • Interfacial delamination between domains under cyclic loading
  • sol-gel infiltration depth variation (target ±15 μm uniformity)
  • calcium borate crystallization inconsistency affecting release predictability (require ±8% batch-to-batch RSD control via DSC verification)
Patsnap Eureka Solution